Jun 16, 2026 | BridgeBio BBP-418 Sweeps LGMD Phase 3; FDA Scrutinizes Moderna Flu Vaccine

BridgeBio's BBP-418 sweeps Phase 3 in limb-girdle muscular dystrophy — stock up 15%, no approved competition. FDA briefing docs challenge Moderna mFlusiva efficacy ahead of Thursday's VRBPAC vote. Plus Lilly acquires non-opioid pain startup 4E Therapeutics, Edgewise advances EDG-7500 toward Phase 3 in HCM, and Neumora abandons navacaprant after two Phase 3 failures.Visit www.thepharmacloseput.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, BridgeBio, BBP-418, LGMD, limb-girdle muscular dystrophy, Moderna, mFlusiva, VRBPAC, flu vaccine, Eli Lilly, 4E Therapeutics, non-opioid pain, MNK inhibitor, Edgewise, EDG-7500, HCM, hypertrophic cardiomyopathy, Adaptive Biotechnologies, MRD, Neumora, navacaprant, myelofibrosis, Jakafi, Be Biopharma, enGene, Parabilis, biotech IPO, Colorado drug import, Lilly, Novartis